Literature DB >> 8875193

Precursors of prostatic cancer: progression, regression and chemoprevention.

R Montironi, C C Schulman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8875193     DOI: 10.1159/000474162

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  6 in total

Review 1.  Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.

Authors:  R Montironi; R Mazzucchelli; J R Marshall; P H Bartels
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

2.  Prognostic factors in prostate cancer.

Authors:  R Montironi
Journal:  BMJ       Date:  2001-02-17

3.  Expression of pi-class glutathione S-transferase: two populations of high grade prostatic intraepithelial neoplasia with different relations to carcinoma.

Authors:  R Montironi; R Mazzucchelli; D Stramazzotti; R Pomante; D Thompson; P H Bartels
Journal:  Mol Pathol       Date:  2000-06

4.  Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917.

Authors:  James R Marshall; Catherine M Tangen; Wael A Sakr; David P Wood; Donna L Berry; Eric A Klein; Scott M Lippman; Howard L Parnes; David S Alberts; David F Jarrard; W Robert Lee; J Michael Gaziano; E David Crawford; Benjamin Ely; Michael Ray; Warren Davis; Lori M Minasian; Ian M Thompson
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-06

5.  A basal cell defect promotes budding of prostatic intraepithelial neoplasia.

Authors:  Mengdie Wang; Raymond B Nagle; Beatrice S Knudsen; Gregory C Rogers; Anne E Cress
Journal:  J Cell Sci       Date:  2016-09-08       Impact factor: 5.285

6.  Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.

Authors:  M Hammad Ather; Farhat Abbas; Nuzhat Faruqui; Mohammad Israr; Shahid Pervez
Journal:  BMC Urol       Date:  2008-12-30       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.